BioLeonhardt – Has developed a programmable implantable stem cell pump and electrical stimulator combination for treating advanced heart failure. The stem cell pump is implanted in the patient’s abdomen and has a silicone septum which allows re-loading via a micro needle syringe of stem cells, genes, growth factors and nutrient hydrogels. The pump is attached to a combination coaxial reinforced infusion catheter and electrical conduction lead which has its tip lodged into the patient’s damaged heart tissue with a special lock-in place nitinol assembly tip. BioLeonhardt is teamed with Core Manufacturing LLC, a Alfred Mann Companies spin out, that is staffed with members that have brought to market leadership already a number of implantable pumps and electrical stimulation devices including the Pacesetter Systems Heart Pacer sold to Siemans and St. Jude Medical, the MiniMed implantable insulin pump sold to Medtronic for $4.3 billion and the Advanced Bionics implantable pain relief pumps sold to Boston Scientific for $800 million – www.core-manufacturing.com
BioLeonhardt is initiating work with Dr. Deepak Srivastava at the Gladstone Institute in San Francisco in collaboration with Dr.Eric Ducker’s team in Utrecht to move forward the first combination therapy for heart failure utilizing MicroRNAs, genes, cells, electrical stimulation and an implantable stem cell pump.
BioLeonhardt is incubating in the Leonhardt Venture’s Cal-X Stars Business Accelerator in Santa Monica – www.calxstars.com ;
About Leonhardt Ventures: Since 1982 Leonhardt Ventures – www.leonhardtventures.com – has a strong history of inventing, developing, backing and bringing to market leadership products for treating heart and cardiovascular disease. Over 200,000 patients have been treated to date with Leonhardt inventions generating more than $3 billion in revenues. The Leonhardt team pioneered cardiovascular balloon catheters in the 80’s, stent grafts and percutaneous heart valves in the 90’s, stem cell therapies and cardiovascular genetic tests in the 2000s and electrical energy stem cell therapy devices, biological pacemakers and implantable pumps in the 2010’s. Leonhardt Venture’s started the Cal-X Stars Innovation and Business Accelerator in 2012 to guide forward cardiovascular and social good impact innovations over a 5 year period in preparation for a listing on the future California Stock Exchange (SEC registration pending).
The Leonhardt Venture’s Cal-X Stars Business Accelerator, Inc. – www.calxstars.com is a a California based laboratory, incubator and accelerator that works closely Leonhardt Ventures to accelerate forward the development and commercialization of promising cardiovascular and social good impact innovations. 75% of the innovations are internally developed and patented by the Leonhardt Ventures team and 25% are acquired, licensed or partnered with outside firms such Cardiobridge, Procyrion and Degreed.com.
Jane Reedy the former VP of Clinical Affairs & Marketing at HeartWare and Thoratec executive and Suresh Gurunathan Director of Engineering at Nanostim have recently joined our advisory team.
Note – Bioheart will receive royalties and milestone payments from MyoStim Pacers, BioPace and BioLeonhardt.
Earlier this year 2013 Howard Leonhardt presented his 25 Year Experience with Stem Cell Transplantation for Heart Failure Treatment – here is a link to the summary abstract – http://prn.to/10W8qbS. Leonhardt an inventor has over 21 patents related to cardiovascular and stem cell therapies. In the 1980’s and early 90’s he patented a number of stem cell delivery catheters including the Pro-Cell delivery system U.S. Patent 5,693,029 http://www.google.com.br/patents/US5693029. He worked with Dr. Stuart Williams in the early 90’s to develop the first cell seeded and sodded stent grafts. A team he led with Dr. Ken Thomson completed the first percutaneous stent graft implantation for aortic aneurysm repair in Melbourne, Australia in 1995. In 1996 with Dr. Christoph Neinaber they completed the first percutaneous repair of an aortic Type B dissection and later published the first-in-man study in The New England Journal of Medicine. In 1997 Leonhardt patented and developed the first Percutaneous Heart Valve U.S. patent 5,957,949 which included cell seeding of the heart valve leaflets – http://www.google.com.mx/patents/US5957949. In 1999 Leonhardt recruited Dr. Race Kao (first to publish in The Physiologist in 1989) and Dr. Doris Taylor (landmark study in Nature Medicine 1998) and founded Bioheart, Inc. the first muscle stem cell company to treat heart failure. In 2001 Leonhardt helped lead the team with Prof. Patrick Serruys, Dr. Doris Taylor and Dr.Warren Sherman that completed the first-in-man non-surgical percutaneous implantation of stem cells to treat a damaged heart in The Netherlands. Bioheart MyoCell is now in the Phase III MIRROR pivotal trial. Leonhardt’s team has developed a number of other breakthrough developments including the first Stem Cell Bra, the first implantable Stem Cell Pump and the first wireless energy devices to direct stem cell therapies non-invasively (AortaCell).
Howard Leonhardt is devoting a substantial part of his time today preparing for new first-in-man implantations of breakthrough stem cell innovations. These include the first stem cell recruiting CRT/ICD heart failure pacemaker following his own patents licensed by the firm Leonhardt Ventures has funded MyoStim Pacers www.myostimpacers.com based in San Diego. This first-in-man implantation pilot study team will be led by Dr. William Abraham of OSU and Dr. Barry Greenberg of UCSD. BioPace is the first biological pacemaker made entirely of living cells – led by Leonhardt Venture’s team member Wendell King, the original inventor of the first biological pacemaker in 1989 patent 5,103,821 http://www.google.sc/patents/US5103821, and also following Taheri-Leonhardt U.S. Patent 6,690,970 issued in 2004 http://www.google.ca/patents/US6690970 (valid til 2023 with ext.). BioPace is on schedule with a goal to complete the first-in-man implantation in Utrecht, The Netherlands by a team led by Dr.Eric Duckers and Dr. Peter Doevendans by late 2014 or 2015.
BioLeonhardt is initiating work with Dr. Deepak Srivastava at the Gladstone Institute in San Francisco in collaboration with Dr.Eric Ducker’s team in Utrecht to move forward the first combination therapy for heart failure utilizing MicroRNAs, genes, cells, electrical stimulation and an implantable stem cell pump. The Leonhardt Ventures team is working with Dr. Mark Cunninghamat USC Keck Medical Center to advance forward the use of circulatory assist pumps to improve stem cell transplantation results in advanced heart failure patients. The Leonhardt Venture’s Stem Cell Bra team is working with Dr. Joel Aronowitz of Cedars Sinai Los Angeles and Dr. Stuart Williams at the University of Louisville to carefully study the safety and efficacy of the world’s first stem cell recruiting women’s bra and other stem cell transplantation techniques (BioCell Tharapies, Minneapolis) for breast reconstruction following cancer.
Nov. 18th, 2013 – Leonhardt Ventures’ Cal-X Stars Business Accelerator, Inc. announced a $15 million financing to accelerate its portfolio innovations forward under the new JOBS ACT Title II 506c exemption – http://prn.to/HVj1yx
About Leonhardt Ventures: Since 1982 Leonhardt Ventures has a strong history of inventing, developing, backing and bringing to market leadership products for treating heart and cardiovascular disease. Over 200,000 patients have been treated to date with Leonhardt inventions generating more than $3 billion in revenues. The Leonhardt team pioneered cardiovascular balloon catheters in the 80’s, stent grafts and percutaneous heart valves in the 90’s, stem cell therapies and cardiovascular genetic tests in the 2000s and electrical energy stem cell therapy devices, biological pacemakers and implantable pumps in the 2010’s. Leonhardt Venture’s started the Cal-X Stars Innovation and Business Accelerator in 2012 to guide forward cardiovascular and social good impact innovations over a 5 year period in preparation for a listing on the future California Stock Exchange (SEC registration pending).
Contact: Howard Leonhardt, Leonhardt Ventures’ Cal-X Stars Business Accelerator, Inc., 1531 6th Street, Unit 401, Santa Monica, California, 90401, Office direct 310 310 2534, Email firstname.lastname@example.org
BIO-LEONHARDT Chairman of the Board & CEO
Leonhardt patent list – http://patents.justia.com/inventor/howard-j-leonhardt
Howard Leonhardt is an inventor and serial entrepreneur. He has 21 U.S. patents for products for treating cardiovascular and heart disease. These include; cardiovascular balloon catheters, stent grafts for aneurysm repair, percutaneous heart valves, heart pacemakers with stem cell recruiting capabilities, electrical stimulation devices for promoting blood flow, electrical stimulation device for converting stem cells to heart muscle, stem cell compositions for heart repair, stem cell delivery systems, biological pacemakers, stem cell bra, stem cell pump, heart valve decalcification devices, heart valve leaflet cell seeding device and artificial lung catheter. His TALENT stent graft developed in the early 1990′s holds a leading world market share for repairing aortic aneurysms without surgery. His inventions have treated over 200,000 patients in 60 countries. In early 1999 Leonhardt founded Bioheart, Inc. www.bioheartinc.com a leader in applying adult muscle stem cells to treat heart failure. Bioheart has raised over $105 million in paid in capital and additionally $40 million in loans and grants. Bioheart MyoCell is in Phase II/III clinical trials at 33 leading centers in the USA (The MARVEL Study). MARVEL Phase II/IIIa part I results were published in the American Heart Journal October of 2011 and demonstrated Bioheart MyoCell patients improved 95.7 meters in exercise capacity over placebo patients receiving optimal CHF drugs, whom declined minus 4 meters. Leonhardt holds a Diploma in International Trade from Anoka Technical College. He attended the University of Minnesota and Anoka Ramsey Community College. He holds an honorary Doctorate in Biomedical Engineering from the University of Northern California and is an honorary alumnus of the University of Florida and Florida International University where he has served on various boards. He was South Florida Entrepreneur of the Year 2003 and State of Florida Entrepreneur of the Year 2004. Leonhardt has founded 28 companies to date, most them majority funded by his venture firm Leonhardt Ventures and their associated angel networks www.leonhardtventures.com.
BioLeonhardt building the ultimate team alliance of all-star collaboration partners.
* Important Note – At this early launch stage it is the full intention of BioLeonhardt to complete all these collaborative agreements but they are not concluded at this time only proposed. The concerned parties wish to see seed funding for BioLeonhardt in place first for the most part.
• MicroRNAs – Iperian, Inc. San Francisco – www.iperian.com – backed by the leading Life Science VCs in the world. Top notch scientific team.
• Electrical stimulation – MyoStim Pacers San Diego – www.myostimpacers.com – 3 pioneering patents covering use of electrical stimulation for myogenesis and arteriogenesis.
• Cardiac Stem Cells – Frati Group Rome, Italy – http://onlusfuturaricerca.com/incs/cv-GiacomoFrati.pdf – Originator of many of the patents covering cardiac stem cell technologies. We are also considering to partner with Capricor in Los Angeles for this segment of our technology. It is our understanding that the Frati team in Rome has licensed Capricor certain related patents for the U.S. market only.
• Nutrient Hydrogels – UC Davis team Sacramento – http://www.bme.ucdavis.edu/revzin/files/2010/11/2000-2007-11.pdf
• Immature Myoblasts – Bioheart, Inc. www.bioheartinc.com – leader of myoblast technologies for heart repair since 1999.
• Adipose derived cells – Tissue Genesis Inc. Honolulu, Hawaii www.tissuegenesis.com – leader in adipose derived cells for nearly a decade.
• SDF – 1 – Ono Pharmaceutiucals Japan – www.ono.co.jp/eng/ – originator of SDF-1 protein technologies for supporting cell transplantation and healing.
BioLeonhardt plans to pay a 7% commission on all net sales to all enforceable patent holders listed above. 1% each for the 7 major components of the technology.
BioLeonhardt will pay a 3% commission on all sales in Italy to BioLeonhardt Italy lead by Mr. Vincenzo Iuri that helped broker the relationship with Dr. Frati and his associates in Rome where the initial studies will take place in addition to the Erasumus University and University of Utrecht in The Netherlands with Professor Eric Duckers. BioLeonhardt Germany and BioLeonhardt Netherlands are also being formed to support the parent company.